MINNEAPOLIS, June 01, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. PBLA, a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces a poster presentation highlighting the results for CPP-1X (also known as α-Difluoromethylornithine (DFMO) or Eflornithine) in recent onset type 1…Read More
Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting Evaluating the Potential of CPP1X Eflornithine in Recent Onset Type 1 Diabetes Panbela Therapeutics NASDAQPBLA
